Results 151 to 160 of about 72,871 (224)

Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study. [PDF]

BMC Infect Dis
Lin WK, Lin SJ, Chang YH, Wang FD, Nguyen PA, Phuc PT, Burton W, Hien NTK, Lin CC, Lam CS, Ha TC, Lu CY, Huang CW, Yang HC, Lin SM, Yang C, Wang LH, Hsu JC.   +17 more
europepmc   +1 more source

Addressing model overcomplexity in drug-drug interaction prediction with molecular fingerprints. [PDF]

J Cheminform
Gil-Sorribes M, Molina A.
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study. [PDF]

Nat Commun
Guo Z, Wei Y, Lin G, Jia KM, Boyer C, Wang H, Li C, Hung CT, Yam CHK, Chow TY, Zhao S, Li K, Yang A, Mok CKP, Hui DS, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

HIV-1 drug resistance among HIV/HCV co-infected patients with treatment failure in Yunnan, southwestern China: a cross-sectional study. [PDF]

Front Microbiol
Li H, Ma X, Li Y, He C, Zou F, Kang X, Zhong M.   +6 more
europepmc   +1 more source

Optimized Milling Approaches for Scalable Production of Ritonavir Nanocrystals: from Process Design to Bioperformance Evaluation. [PDF]

ACS Omega
da Cunha Chaves MH, Alexandrino-Júnior F, Sarcinelli MA, Gomes-da-Silva NC, Santos-Oliveira R, Amendoeira FC, Antunes Rocha HV.   +6 more
europepmc   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency. [PDF]

J Hum Immun
Gilbert KM, Aglan M, Jogdand A, Khairnar NV, Ssemaganda H, Ong MS, Farmer JR.   +6 more
europepmc   +1 more source

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study. [PDF]

Nat Commun
Chong KC, Wei Y, Wong CKH, Xiong X, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Guo Z, Li K, Yang A, Mok CKP, Hui DSC, Zhao S, Yeoh EK, Lin G.   +16 more
europepmc   +1 more source